购物车 
-
Erythromycin
NMR and HPLC COA下载 MSDS下载 - Names：
Erythromycin, Macrolide antibiotic
- CAS号：
114-07-8
MDL Number： MFCD00084654 - MF(分子式)： C37H67NO13 MW(分子量)： 733.93
- EINECS:204-040-1 Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
红霉素(114-07-8,Erythromycin)是一种广谱的大环内酯类抗生素，具有抗菌活性。 红霉素通过细菌细胞膜扩散，并与细菌核糖体的50S亚基可逆结合。 这样可以防止细菌蛋白质的合成。 红霉素可能具有抑菌作用或杀菌作用，这取决于感染部位的药物浓度和所涉生物体的敏感性。
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| SS0402-25g | 25g | USP | ¥ 896.00 | ¥ 896.00 | 3-5days | ¥ 0.00 | ||
| SS0402-5g | 5g | USP | ¥ 199.00 | ¥ 199.00 | 3-5days | ¥ 0.00 | ||
| SS0401-25g | 25g | EP | ¥ 568.00 | ¥ 568.00 | 3-5days | ¥ 0.00 | ||
| SS0401-5g | 5g | EP | ¥ 126.00 | ¥ 126.00 | 3-5days | ¥ 0.00 |
| 中文别名 | 114-07-8;红霉素;红霉素碱;罗红霉素EP杂质A;大环内酯类抗生素 |
| 英文别名 | Erythromycin;(-)-Erythromycin;Erythromycin A;E-Mycin;ROBIMYCIN;UNII-63937KV33D;Theramycin Z;E-BASE;Inderm;Erythromast 36;Retcin;Ak-Mycin;Dotycin |
| CAS号 | 114-07-8 |
| Inchi | InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1 |
| InchiKey | ULGZDMOVFRHVEP-RWJQBGPGSA-N |
| 分子式 Molecular Weight | C37H67NO13 |
| 分子量 Formula | 733.93 |
| 溶解度Solubility | DMSO : ≥ 100 mg/mL (136.25 mM) H2O : < 0.1 mg/mL (insoluble) |
| 性状 | 白色至灰白色固体粉末 |
| 储藏条件 Storage conditions | storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years) |
红霉素(114-07-8,Erythromycin)毒性测试：
| 生物 | 测试类型 | 路线 | 报告剂量（标准化剂量） | 影响 | 参考 |
|---|---|---|---|---|---|
| child | TDLo | oral | 10mg/kg/1D-I (10mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Annals of Internal Medicine. Vol. 115, Pg. 69, 1991. |
| child | TDLo | oral | 250mg/kg (250mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING GASTROINTESTINAL: OTHER CHANGES BLOOD: CHANGES IN LEUCOCYTE (WBC) COUNT |
Pediatrics. Vol. 90, Pg. 624, 1992. |
| dog | LDLo | unreported | > 100mg/kg (100mg/kg) | Antibiotics and Chemotherapy Vol. 2, Pg. 281, 1952. | |
| guinea pig | LD50 | intraperitoneal | 413mg/kg (413mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 41, Pg. 555, 1952. | |
| hamster | LD50 | oral | 3018mg/kg (3018mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 41, Pg. 555, 1952. |
| mouse | LD50 | intramuscular | 394mg/kg (394mg/kg) | Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 44, Pg. 199, 1955. | |
| mouse | LD50 | intraperitoneal | 280mg/kg (280mg/kg) | Journal of Antibiotics. Vol. 43, Pg. 938, 1990. | |
| mouse | LD50 | intravenous | 426mg/kg (426mg/kg) | "Index of Antibiotics from Actinomycetes," Umezawa, H. et al., eds., Tokyo, Univ. of Tokyo Press, 1967Vol. -, Pg. 273, 1967. | |
| mouse | LD50 | oral | 2580mg/kg (2580mg/kg) | Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 31, Pg. 241, 1974. | |
| mouse | LD50 | subcutaneous | 1800mg/kg (1800mg/kg) | Antibiotics and Chemotherapy Vol. 2, Pg. 281, 1952. | |
| rat | LD50 | oral | 4600mg/kg (4600mg/kg) | Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 31, Pg. 241, 1974. | |
| rat | LDLo | subcutaneous | 427mg/kg (427mg/kg) | Compilation of LD50 Values of New Drugs. |
红霉素(114-07-8,Erythromycin)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品时尽量采用多个药勺分别使用，使用后清洗干净后，烘干消毒存放。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
Erythromycin(114-07-8) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tag:红霉素(114-07-8,Erythromycin),红霉素试剂,红霉素的杂质,红霉素的纯度,红霉素的外观,红霉素的溶解度,红霉素的价格,红霉素的厂家,红霉素的作用,红霉素的MSDS,红霉素的合成,红霉素的注意事项
| 产品说明 | 红霉素(114-07-8,Erythromycin)是一种广谱的大环内酯类抗生素，具有抗菌活性。 红霉素通过细菌细胞膜扩散，并与细菌核糖体的50S亚基可逆结合。 这样可以防止细菌蛋白质的合成。 红霉素可能具有抑菌作用或杀菌作用，这取决于感染部位的药物浓度和所涉生物体的敏感性。 |
| Introduction | Erythromycin (114-07-8,红霉素) is a macrolide antibiotic produced by actinomycetes. Erythromycin has a wide range of antibacterial activities. |
| Application1 | 红霉素可能具有抑菌作用或杀菌作用 |
| Application2 | A macrolide antibiotic protein synthesis inhibitor.Erythromycin is an antibiotic produced by growth of certain strains of Streptomyces erythreus. This product is composed largely of erythromycin A with small amounts of erythromycins B and C and is recommended for concentration at 100 mg/L. Concentrations between 50 and 200 mg/L have also proven effective in controlling bacterial growth. Erythromycin has been used as a motilin receptor agonist, to block respiratory glycoconjugate secretion in human airways in vitro, and for selecting plasmid-cured and recombinant lactococcus lactis MG1363 strains. |
| Application3 | Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin (IC50=1.5 μg/ml). |
Erythromycin is a broad-spectrum, macrolide antibiotic with antibacterial activity. Erythromycin diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.
| 警示图 | |
| 危险性 | warning |
| 危险性警示 | No data available |
| 安全声明 | H303 |
| 安全防护 | P312 |
| 备注 | 实验过程中防止吸入、食入，做好安全防护 |
| 象形图 |   |
|---|---|
| 信号警告 | Danger |
| GHS危险说明 |
Aggregated GHS information provided by 163 companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 66 of 163 companies. For more detailed information, please visit ECHA C&L website Of the 8 notification(s) provided by 97 of 163 companies with hazard statement code(s): H317 (36.08%): May cause an allergic skin reaction [Warning Sensitization, Skin] H319 (63.92%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H334 (35.05%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
| 防范说明代码 |
P261, P264, P272, P280, P285, P302+P352, P304+P341, P305+P351+P338, P321, P333+P313, P337+P313, P342+P311, P363, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| High performance of molecularly imprinted polymer for the selective adsorption of erythromycin in water(Colloid and Polymer Science,2020) |
| Influence of solvents on the variety of crystalline forms of erythromycin(AAPS PharmSci,2003) |
| Insights into resistance mechanism of the macrolide biosensor protein MphR(A) binding to macrolide antibiotic erythromycin by molecular dynamics simulation |
| Combined available nitrogen resources enhanced erythromycin production and preliminary exploration of metabolic flux analysis under nitrogen perturbations(Bioprocess and Biosystems Engineering,2019) |
| Antimicrobial resistance pattern, virulence determinants and molecular analysis of Enterococcus faecium isolated from children infections in Iran(BMC Microbiology,2019) |
1. A novel fluorinated erythromycin antibiotic
Rebecca J. M. Goss* and Hui Hong. Chem. Commun., 2005, 3983–3985
This work focuses on the generation of novel fluorinated erythromycin. Analogues of erythromycin in which the macrolide is fluorinated have been generated synthetically, but to date only one example bearing a fluorine in the alkyl side chain has been made. Propionyl coenzyme A (CoA) is the natural starter unit for erythromycin biosynthesis by Saccharopolyspora erythraea and its incorporation leads to the production of erythromycin A 1 (Fig. 1). The loading module of the erythromycin producing polyketide synthase (PKS) 6-deoxyethronolide B synthase (DEBS) is highly selective for propionyl CoA, though it can also accept acetyl CoA. Two different methods of increasing the breadth of starter unit specificity have been explored. The first method, employed by workers in the United States, involves the generation of a strain in which a genetic block is introduced in the first condensation step of erythromycin biosynthesis, the resultant strain is unable to produce polyketide macrolide unless N-acetylcysteamine (NAC) thioesters of a diketide are administered. There has been a recent report of the application of this method to make 15-fluoro-6-deoxyethronolide B.
2. Erythromycin B: conformational analysis and antibacterial activity
Paul Tyson, Abdolreza Hassanzadeh, Jill Barber*. Med. Chem. Commun., 2011, 2, 331–336
Erythromycin A is more abundant and therefore easier to isolate than erythromycin B. Presumably because of the success of erythromycin A, erythromycin B has been largely neglected by the pharmaceutical industry. Recently, however, we have high-lighted a number of advantages of erythromycin B over erythromycin A. Firstly, it is much more stable to acid, because it is unable to cyclize in a 12,9-direction; erythromycin A undergoes facile formation of the spiro-6,9:12,9-cyclized anhydroerythromycin A, which has little or no antibacterial activity. The 2’-esters of erythromycin B are also much more stable to acid than those of erythromycin A. This ?nding is potentially important in paediatric medicine, in which 2’-esters serve as pro-drugs.Finally, we have been able to derivatize erythromycin B to give pro-pro-drugs, for example erythromycin B enol ether ethyl succinate (3), which are almost insoluble in the medicine bottle and therefore unable to hydrolyse to yield the vile-tasting erythromycin free base. Compound 3 is activated in two stages, as shown in Scheme 1, to yield erythromycin B.
3. Methods and options for the heterologous production of complex natural products
Haoran Zhang, Brett A. Boghigian, John Armando and Blaine A. Pfeifer*. Nat. Prod. Rep., 2011, 28, 125–151
Having established 6dEB production from either S. coelicolor or S. lividans, there was still the need to convert this polyketide intermediate to full erythromycin. However, as opposed to building upon 6dEB biosynthesis in CH999 (as would be expected given the incorporation of the ermE resistance gene), puri?ed 6dEB produced from CH999 production cultures was exogenously fed to mutants of S. erythraea, allowing subsequent conversion to full erythromycin. Using this strategy, numerous rationally designed 6dEB derivatives were generated using the Streptomyces strains and these analogs were then converted to erythromycin derivatives via converter S. erythraea strains.
对不起，暂无产品评价！
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色，是通过细胞爬片是让玻片浸在细胞培养基内，细胞在玻片上生长，主要用于组织学，免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有：异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
细胞培养耗材技术领先性
细胞培养板行业面临的核心痛点是：常规TC处理后表面亲水角随时间衰减，影响长期培养稳定性，BIOFOUNT高分...
2026/4/28 15:12:51
细胞培养耗材关键性能
细胞培养板的水接触角作为表面润湿性的核心指标，直接影响细胞贴壁、增殖、分化及功能表达，其中40°（低接触角/...
2026/4/28 14:52:44
chelex 100树脂国产替代之路-BIOFOUNT范德生物
Chelex 100螯合离子交换树脂对铜、铁和其他重金属?的偏好显著高于对钠、钾等一价阳离子的偏好。它对二价...
2025/11/4 14:22:46
9月开学季——助研新学期 范德送好礼
2025/8/28 15:30:55
Waxfilm 实验室封口膜：技术与国际市场的双重突破
在实验室耗材领域，封口膜是保障实验准确性与稳定性的关键产品之一。近年来，Waxfilm?实验室封口膜凭借其卓...
2025/5/13 13:03:40
Waxfilm实验室封口膜的5大突破
Waxfilm实验室封口膜作为生物功能膜领域的国产技术突破和品牌突破，是生物领域中国技术发展的缩影。
2025/5/6 17:02:07
各种微流控芯片键合方法的优缺点
微流控芯片键合：目前主要有激光焊接、热压键合、胶键合、超音波焊接，每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案：微流控芯片制造的一个重要环节，也是最容易被忽视的--芯片键合。其中一个重要因素是：微流控...
2023/7/27 12:44:28
